Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of masitinib plus standard therapy in mild to moderate Alzheimer's disease
2010-021218-50Phase 3Withdrawn
- Sponsor
- AB Science
- Start
- Jul 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Alzheimer's disease (AD) comparing Masitinib arm with Placebo arm (2 arms). Primary endpoints: Co-primary efficacy endpoints and Safety endpoints. Planned start Jul 2010; status: withdrawn.
02
Drugs
masitinib
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on 2010-021218-50.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-021218-50.